Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 14.06M P/E - EPS this Y 49.20% Ern Qtrly Grth -
Income -14.19M Forward P/E -1.81 EPS next Y 31.60% 50D Avg Chg 19.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 0.70 EPS next 5Y - 52W High Chg -93.00%
Recommedations 1.50 Quick Ratio 4.05 Shares Outstanding 1.18M 52W Low Chg 65.00%
Insider Own 2.29% ROA -58.53% Shares Float 1.16M Beta 1.30
Inst Own 2.89% ROE -110.09% Shares Shorted/Prior 49.49K/111.89K Price 2.10
Gross Margin - Profit Margin - Avg. Volume 334,030 Target Price 33.75
Oper. Margin - Earnings Date Nov 7 Volume 83,976 Change -0.94%
About Palisade Bio, Inc.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Palisade Bio, Inc. News
09/16/24 Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
09/05/24 Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
08/19/24 Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/13/24 Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
08/08/24 Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
07/31/24 Palisade Bio Participates in Virtual Investor “What this Means” Segment
07/29/24 Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
07/19/24 Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
07/11/24 Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
06/24/24 Palisade Bio to Participate in the Virtual Investor Closing Bell Series
06/21/24 Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
06/11/24 Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
06/10/24 Palisade Bio to Present at the Virtual Investor Pitch Conference
05/21/24 Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
05/14/24 Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
05/07/24 Palisade Bio Appoints Margery Fischbein to its Board of Directors
05/07/24 Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
05/02/24 Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
05/01/24 Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
04/23/24 Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
PALI Chatroom

User Image WallStreetBuyDip Posted - 20 hours ago

I'm especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I'll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.

User Image faraico Posted - 1 day ago

$PALI CTA submitted A CTA must be filed prior to the initiation of a clinical trial in Canada. HPFB must review the application and notify the sponsor within 30 days Tiberio Faoro: until 15 october 2024 we will have the Canada approvaò for phase 1 human trial

User Image faraico Posted - 2 days ago

$PALI https://palisadebio.com/precision-medicine/

User Image Kennyk93 Posted - 3 days ago

$PALI they're doing the appropriate steps to bring a drug to market. Will it reflect in the share price? Who knows

User Image Stock_Titan Posted - 4 days ago

$PALI Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies https://www.stocktitan.net/news/PALI/palisade-bio-launches-new-corporate-branding-and-reiterates-2h3n3wek7haf.html

User Image faraico Posted - 4 days ago

$PALI changed website and logo. And put a picture of a woman playing padel....

User Image Stocksrockman Posted - 4 days ago

$ALT $MCVT $PALI $SING If I was going to put my hands all of some DD, it would have to be that of MCVT

User Image BullishEagles Posted - 4 days ago

$MCVT Buying 10k shares here tomorrow - Positive PR with a huge volume spike Friday! Small float moving! $SING Will we see it back above 1$ ? $ALT Huge rally about to happen here $PALI News due

User Image WallStreetBuyDip Posted - 1 week ago

I'm especially more strict when it comes to trading Small + Mid caps. Some trade based on momentum or catalyst, I only buy when H% is low, nothing else. Next I'll trade $PALI + $MMAT I keep a result summary to see if the strategy has been successful or not.

User Image faraico Posted - 1 week ago

$PALI

User Image Kennyk93 Posted - 1 week ago

$PALI interesting

User Image AKIREICH Posted - 1 week ago

$PALI

User Image faraico Posted - 1 week ago

$PALI

User Image Clairenova Posted - 1 week ago

$PALI why is this stock down while there seems a good news?

User Image AKIREICH Posted - 2 weeks ago

User Image Fast_Eddie_Felson Posted - 2 weeks ago

$PALI i’m not even sure how they can keep saying that the fucking Ph 1 trials will commence in 2024 when there isn’t even an IND and the FDA has not even approved it. On top of the recruiting effort to even start. Is someone even reviewing these garbage PRs?

User Image Kennyk93 Posted - 2 weeks ago

$PALI lol

User Image AKIREICH Posted - 2 weeks ago

$PALI it's time!!!

User Image DARKP00L Posted - 2 weeks ago

$PALI Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

User Image ACInvestorBlog Posted - 2 weeks ago

$PALI Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

User Image Stock_Titan Posted - 2 weeks ago

$PALI Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification https://www.stocktitan.net/news/PALI/palisade-bio-reports-data-demonstrating-pde4b-expression-in-patient-qlswv72f9y4y.html

User Image kk850850 Posted - 2 weeks ago

$PALI Does anyone still remember the CVR issued by SNCA (the previous name of PALI) in 2021 for the merger? I want to know if this thing is still worth looking forward to?

User Image GansoManso Posted - 2 weeks ago

$PALI The mafia broker banks, along with dirty hedge funds like Intracoastal, Sabby and Armistice, and investment banks like H.C. Wainwright, have taken your money. And this company's execs helped them do it with their incessant reverse splits, deliberate dilution and taking of toxic financing. How much are the execs getting paid for screwing retail shareholders? "... this really should be front page news, but the banks and brokers have big marketing budgets, so i imagine there will be very little coverage on this important news for investors in North America." The SEC was created and is controlled by the mafia broker banks, so don't expect them to do anything. Musk aptly dubbed them the "Short-Sellers Enrichment Commission". The only way to win is to stop playing their game. Instead, invest in ammo... not the ticker. https://finance.yahoo.com/news/end-naked-short-selling-230100677.html?guce_referrer=aHR0cHM6Ly93d3cuYmluZy5jb20v&guce_referrer_sig=AQAAAEg4_ra_uhbMoBbyVjhIRSOJqSlvjmByE_BwR27RFFtzghYSYnV9THkf-j7qc_AwjgcoWD1euIBQWwGKdNUtBpSmzFu6TarMAnOdbh6t4UQ9Lm4ojf6uamskgwhQy4Ct-0gfx19CCq-8-aLzLZrY5Cd5bL9RAveuQ1NEMKWSttF0&_guc_consent_skip=1725227371

User Image Enfuzion Posted - 08/28/24

$PALI A follow up. I had some doubts that the drug would act across the entire colon, but the preclinical data suggests that it does. The science seems to check out (drug target and application); although it's still early days. This needs to complete phase 1 before I consider entering. In my opinion, this needs more de-risking financially and scientifically. I'll be watching from the sidelines for now.

User Image swimmingthinker2 Posted - 08/26/24

$PALI Ok at least we are getting closer to 2$ at which point I can average down my 95$ breakeven lmao

User Image faraico Posted - 08/26/24

$PALI does someone have the Seneca CVR's in the bank account? I have them in my account and bank says I can not close the account.

User Image BigTimePennyStocks Posted - 08/25/24

Small-Cap Watchlist for this Week: ( $NIVF, $VVPR, $EFSH, $FLYE, $PALI ) #NASDAQ #NYSE

User Image Asriel2017 Posted - 08/24/24

$PALI how's the garbage doing?

User Image Kennyk93 Posted - 08/22/24

$PALI tute ownership went from 11 to 2. Not a good sign

User Image Fast_Eddie_Felson Posted - 08/21/24

$PALI nothing happening here for awhile

Analyst Ratings
Maxim Group Buy May 1, 24
Maxim Group Buy Apr 16, 24
Maxim Group Buy Nov 17, 23
Ladenburg Thalmann Buy May 16, 23
Maxim Group Buy Mar 30, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Finley John David CEO, CFO, Director CEO, CFO, Director Jan 31 Buy 0.559 10,000 5,590 74,649 02/01/24
Williams Donald Allen Director Director Jan 31 Buy 0.605 10,000 6,050 30,000 02/01/24
Finley John David CEO, CFO, Director CEO, CFO, Director Dec 11 Option 0.00 5,559 63,340 12/19/23
Williams Donald Allen Director Director Sep 27 Buy 0.54 20,000 10,800 20,000 09/29/23
Finley John David CEO, CFO, Director CEO, CFO, Director Sep 27 Buy 0.5392 15,000 8,088 43,394 09/29/23
Trenschel Robert J. Director Director Sep 14 Sell 0.64 300 192 09/15/23
Finley John David CEO, CFO, Director CEO, CFO, Director Sep 13 Buy 0.655 15,000 9,825 28,394 09/14/23
Finley John David Chief Financial Offi.. Chief Financial Officer Sep 01 Buy 0.1437 19,481 2,799 148,727 09/02/22
Hallam Thomas Chief Executive Offi.. Chief Executive Officer Aug 16 Buy 0.25 40,000 10,000 57,592 08/18/22
Finley John David Chief Financial Offi.. Chief Financial Officer Aug 16 Buy 0.25 100,000 25,000 121,896 08/18/22
Dawson Michael John Chief Medical Office.. Chief Medical Officer Mar 29 Buy 1.1395 15,000 17,092 15,000 03/31/22
Hallam Thomas Chief Executive Offi.. Chief Executive Officer Mar 28 Buy 1.18 10,000 11,800 17,592 03/29/22
Finley John David Chief Financial Offi.. Chief Financial Officer Mar 24 Buy 1.0899 7,500 8,174 21,896 03/25/22
Trenschel Robert J. Director Director Sep 13 Buy 2.83 14,999 42,447 14,999 09/13/21
Finley John David Chief Financial Offi.. Chief Financial Officer Aug 30 Buy 2.64 10,000 26,400 12,396 08/30/21